Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
العنوان: | Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? |
---|---|
المؤلفون: | Jong Sil Lee, Dong Chool Kim, Jung-Hun Kang, Jung Wook Yang, Dae Hyun Song, Gyung Hyuck Ko, Gyeong-Won Lee, Jeong-Hee Lee, Hoon-Gu Kim, In-Suk Kim |
المصدر: | Leukemialymphoma. 50(12) |
سنة النشر: | 2009 |
مصطلحات موضوعية: | Male, Cancer Research, Pathology, medicine.medical_treatment, CHOP, Polymerase Chain Reaction, Antibodies, Monoclonal, Murine-Derived, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Promoter Regions, Genetic, Antibodies, Monoclonal, Hematology, Middle Aged, Prognosis, Immunohistochemistry, Oncology, Vincristine, Rituximab, Female, Lymphoma, Large B-Cell, Diffuse, medicine.drug, Adult, Mucositis, medicine.medical_specialty, Cyclophosphamide, Adolescent, O(6)-Methylguanine-DNA Methyltransferase, Young Adult, medicine, Humans, neoplasms, Aged, Retrospective Studies, Chemotherapy, business.industry, DNA Methylation, medicine.disease, Survival Analysis, digestive system diseases, Lymphoma, Doxorubicin, Multivariate Analysis, Cancer research, Prednisone, business, Diffuse large B-cell lymphoma |
الوصف: | The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab. In this retrospective study, we used the methylation-specific polymerase chain reaction to investigate MGMT promoter methylation status and immunohistochemistry to evaluate MGMT expression in patients with DLBCL who received rituximab plus CHOP (R-CHOP) chemotherapy. No difference in patient characteristics, disease characteristics, response, or survival in patients with DLBCL who received front-line R-CHOP chemotherapy was observed according to MGMT methylation status and MGMT expression. On multivariate analysis, Grade 3-4 mucositis in the MGMT methylated group was significantly higher than that in the MGMT unmethylated group (hazard ratio (HR) 2.40, 95% CIs: 1.26-7.26, p = 0.014). This study demonstrated that inactivation of MGMT does not appear to play an important role in patients with DLBCL who received R-CHOP chemotherapy either with regard to the response rate or overall survival. Additionally, Grade 3-4 mucositis was found to be significantly related with inactivation of MGMT by a multivariate analysis. |
تدمد: | 1029-2403 |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a78d5d3576cba339c2e04b9b3a049aTest https://pubmed.ncbi.nlm.nih.gov/19860620Test |
رقم الانضمام: | edsair.doi.dedup.....13a78d5d3576cba339c2e04b9b3a049a |
قاعدة البيانات: | OpenAIRE |